IndianOil and LanzaTech sign a Statement of Intent to Construct World’s First Refinery Off Gas-to-Bioethanol

Indian Oil Corporation Limited (IndianOil), India’s flagship national oil company and, LanzaTech, carbon recycling company, have signed a Statement of Intent to construct the world’s first refinery off gas-to-bioethanol production facility in India.

LanzaTech has developed a gas fermentation process to make fuels and chemicals. Instead of sugars and yeast, the company uses a biological catalyst to ferment waste gas emissions. The large volume of waste gas produced at industrial facilities such as refineries cannot be stored or transported; rather it must be combusted to make power locally and emitted as carbon dioxide (CO2). Power can be carbon-free, and in India today, the cost of renewable power has fallen below the cost of coal, accelerating the transition to a carbon-free grid. LanzaTech’s technology allows refineries to divert waste gases from the grid, supporting the transition to fully renewable power while recycling this carbon into liquid fuels and petrochemicals.

India is adopting a cleaner and greener economic growth pathway today, with the Government running one of the largest renewable capacity expansion programmes in the world. The implementation of the National Smart Grid Mission, along with new programmes for increasing energy capacities from wind and waste conversion, are key elements of this vision. This vision is inextricably linked to the principle of ‘need-based consumption’ which follows the need to maximise on existing resources and decarbonise everyday activities.

Read more

DuPont and Bock partner to distribute biogas enzyme technology

Industrial enzyme manufacturer DuPont Industrial Biosciences and silage storage specialist Bock UK have announced a strategic partnership where Bock will demonstrate DuPont’s biogas enzyme technology at commercial scale in the UK market. The enzyme technology, OPTIMASH AD-100, has been shown to help biogas producers in the agricultural sector improve yields and process robustness.

OPTIMASH AD-100 works by accelerating the breakdown of various materials such as maize silage, grasses, straw, manures and some food wastes, resulting in sugars more suitable for conversion into biogas. The easy-to-use liquid enzyme product has been shown to produce up to a 13% increase in biogas yields in anaerobic digesters, according to DuPont.

Read more

Fourth industrial revolution is here, claims ARC Laureate Fellow

World-leading IT expert, Professor Svetha Venkatesh, is using pattern recognition and machine learning to explore frontiers in medicine, materials, mental health and many other sectors.

Most of us don’t know the term yet, but the world is on the cusp of a fourth industrial revolution, claims Deakin University’s new Australian Research Council (ARC) Laureate Fellow, Professor Svetha Venkatesh.

Coined by the founder of the World Economic Forum, Professor Klaus Schwab, and the theme of the Forum’s 2016 annual meeting, this revolution is characterised by the embedding of technology within societies – and our bodies.

Read more

DuPont and Bock partner to distribute biogas enzyme technology

Industrial enzyme manufacturer DuPont Industrial Biosciences and silage storage specialist Bock UK have announced a strategic partnership where Bock will demonstrate DuPont’s biogas enzyme technology at commercial scale in the UK market. The enzyme technology, OPTIMASH AD-100, has been shown to help biogas producers in the agricultural sector improve yields and process robustness.

OPTIMASH AD-100 works by accelerating the breakdown of various materials such as maize silage, grasses, straw, manures and some food wastes, resulting in sugars more suitable for conversion into biogas. The easy-to-use liquid enzyme product has been shown to produce up to a 13% increase in biogas yields in anaerobic digesters, according to DuPont.

Read more

National IP firm announces three promotions for 2017

Specialist intellectual property firm Baldwins has announced the promotion of one new Senior Associate and two new Associates.

“We are excited to recognise the development of our IP specialists, it exhibits our commitment to grow the firm and promote from within. The promotions of Kate, Victoria and Harriet reflect their expert IP knowledge and the high quality of service they provide our clients.” – Gay Rankin, General Manager, Baldwins Intellectual Property

Read more

How a key Donald Trump backer lost $22m overnight on an Australian drug company

US congressman Chris Collins has backed two horses in the past 18 months: Donald Trump, and an obscure Australian biotech firm called Innate Immunotherapeutics. Trump turned out to be a winner – Innate has been just the opposite.

On Tuesday, the Sydney-based company announced its lone, promising asset – a multiple sclerosis drug known as MIS416 – had bombed its clinical trial, having shown no meaningful difference to the placebo. Its value plunged 92 per cent.

Read more

Industry-Academia Collaborative Mission for Accelerating Discovery Research to Early Development for Biopharmaceuticals

It is time for India to capitalize now on our unique strengths and overcome any
hurdles to ensure success in the bio-pharmaceutical market.” This was stated by
the Union Minister for Science& Technology and Earth Sciences, Environment,
Forests & Climate Change, Dr. Harshvardhan while addressing the media in
New Delhi today.

The first ever Industry-Academia mission to accelerate biopharmaceutical development in
India has been approved by the Government of India. The program named Innovate
in India (i3) will witness an investment of USD 250 million with USD 125
million as a loan from World Bank and aspires to create an enabling ecosystem
to promote entrepreneurship and indigenous manufacturing in the sector.

Read more

SCT scientists develop Neo-Islet technology for treating insulin-dependent diabetes

The cover of the July 2017 issue of the journal STEM CELLS Translation Medicine showcases the latest advance toward a functional cure of insulin-dependent diabetes. Scientists at SymbioCellTech (SCT), a small biotech company in Salt Lake City, developed a technology that combines Mesenchymal Stem Cells (MSCs) with culture-expanded pancreatic islet cells to form three-dimensional cellular clusters, termed “Neo-Islets”. A single dose of Neo-Islets administered into the abdominal cavity provides durable blood sugar control, i.e., insulin-independence, without the need for potentially toxic anti-rejection drugs or encapsulation devices.

Type-1 diabetes is an auto-immune disease in which the patient’s own immune system attacks and destroys the islet cells in the pancreas resulting in the inability of the body to produce insulin. The standard cell therapy for diabetes is islet cell transplantation into the liver; however, this approach has serious drawbacks: (1) it requires the patient to permanently take potentially-toxic immunosuppression drugs, (2) it cannot be scaled up to treat the large number of patients that would benefit from this therapy because up to 5 donor pancreata are required for a single dose, and (3) it is expensive. In order to avoid the need for immunosuppressive agents, researchers have focused on using various devices that encapsulate islets or other insulin-producing cells. These devices, made of specially-formulated materials, are designed to protect against the immune attack yet allow for glucose-sensitive insulin release. Limited success with this technology has been observed in the lab, but most encapsulation devices have failed due to foreign body reactions.

Read more